MJM. R. Johnson

M. R. Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


M. R. Johnson has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • A.F. Riddle

    The Department of Obstetrics and Gynaecology, and The Harris Birthright Research Centre for Fetal Medicine, King's College School of Medicine and Dentistry Denmark Hill, London SE5 18RX

    3 shared publications
  • J.G. Grudzinskas

    Department of Obstetrics and Gynaecology, The Royal London Hospital Whitechapel, London El 1BB, UK

    3 shared publications
  • Kypros Herodotos Nicolaides

    Harris Birthright Research Centre for Fetal Medicine, King's College Hospital London UK

    3 shared publications
  • O. Ogueh

    Section of Obstetrics and Gynaecology, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK

    3 shared publications
  • V. Sharma

    The Department of Obstetrics and Gynaecology, and The Harris Birthright Research Centre for Fetal Medicine, King's College School of Medicine and Dentistry Denmark Hill, London SE5 18RX

    3 shared publications
  • W.P. Collins

    The Department of Obstetrics and Gynaecology, and The Harris Birthright Research Centre for Fetal Medicine, King's College School of Medicine and Dentistry Denmark Hill, London SE5 18RX

    3 shared publications

Latest Publications

  • Open Access

    The regulation of the human corpus luteum steroidogenesis: a hypothesis?

    by V. J. H. Oon, M. R. Johnson

    The corpus luteum (CL) is an important endocrine organ in the menstrual cycle and in pregnancy. The regulation of its hormonal production has been extensively studied. The steroidogenic abilities of the CL can be rescued by human chorionic gonadotrophin (HCG) but its role in the maintenance of CL function is not clear. We will discuss the hypothesis that there are fetoplacental factors, other than HCG, that modulate CL steroidogenesis.


  • Open Access

    The feto-placental unit stimulates the pregnancy-associated increase in maternal bone metabolism

    by O. Ogueh, G. Khastgir, A. Abbas, J. Jones, K.H. Nicolaides, J.W. Studd, J. Alaghband-Zadeh, M.R. Johnson

    The aim of the study was to investigate role of the feto–placental unit in the pregnancy-induced increase in maternal bone metabolism. To achieve this, circulating concentrations of carboxy terminal pro-peptide of type I pro-collagen (PICP, a marker of bone formation) and cross-linked carboxy terminal telopeptide of type I collagen (ICTP, a marker of bone resorption) were measured in three groups of pregnant women. Group 1 comprised 12 women with singleton pregnancies; group 2, nine women with twin pregnancies; and group 3, 19 women with multifetal pregnancies (≥3 fetuses) before and after selective fetal reduction to twin pregnancies. Blood samples were obtained at 10–12 weeks gestation (groups 1–3, pre-fetal reduction in group 3) and 4 weeks and 8 weeks later (groups 2 and 3). Before fetal reduction there was a significant correlation between the number of fetuses and the concentrations of both PICP and ICTP (r = 0.503 and P = 0.001 and r = 0.573 and P < 0.001 respectively). The circulating concentrations of PICP and ICTP were significantly higher in the pre-reduction multifetal pregnancies than in the twin pregnancies (P < 0.001 and P = 0.0013 respectively). The circulating concentrations of ICTP in multifetal pregnancies fell by 4 weeks after fetal reduction to those observed in control twins. Concentrations of PICP were unaltered after fetal reduction. Higher order multiple pregnancies had the greatest decline in ICTP concentrations. These data suggest that the increased bone turnover observed in the multifetal pregnancies is due to a factor derived from the feto–placental unit and that this factor acts primarily to stimulate bone resorption.


  • Open Access

    Antenatal dexamethasone and the growth hormone–insulin-like growth factor axis

    by O. Ogueh, J.P. Miell, J.C. Jones, J.S. Jones, J. Alaghband-Zadeh, M.R. Johnson

    Dexamethasone administration has marked effects on the growth hormone-insulin-like growth factor axis (GH–IGF) in animal and human studies. During pregnancy in the rat, it is associated with fetal growth restriction due to inhibition of IGF bioactivity. In the human only repeated dosages have been associated with fetal growth restriction. The aim of this study is to test the hypothesis that antenatal dexamethasone administration to pregnant women is associated with reduced activity of the GH–IGF axis. To achieve this blood samples were taken from 12 pregnant women pre- and at 24 h and 48 h after dexamethasone administration. In these samples GH, IGF-I, IGF bioactivity and IGF binding protein (IGFBP)-3 protease activity were measured. In view of the interaction between insulin and the GH–IGF axis, glucose and insulin concentrations were also measured. There were no significant differences between the concentrations of GH, IGF-I, IGF bioactivity and IGFBP-3 protease activity before and after dexamethasone. The concentrations of glucose and insulin were significantly higher at 24 h, but not 48 h post-dexamethasone. It is concluded that a single antenatal course of dexamethasone does not alter the GH–IGF-I axis in pregnant women at the time points studied.


  • Open Access

    The metabolic effect of antenatal corticosteroid therapy

    by O. Ogueh, M.R. Johnson

    The use of antenatal dexamethasone to mature the fetal lung in pregnancies likely to deliver before 34 weeks is almost universal. It reduces the incidence of respiratory distress syndrome in the newborn and results in an overall improvement in neonatal morbidity and mortality. Although considered to be generally safe, there are concerns about adverse maternal and fetal effects. In a series of studies, we have found that antenatal dexamethasone administration is associated with reduced placental hormone production and maternal bone formation, impaired glucose tolerance and altered function of the hypothalamic–pituitary–adrenal axis. In this article, we have compared our data with other reports in the human and reviewed the relevant animal data. We conclude that further studies on the long-term effects of antenatal dexamethasone therapy in the human are warranted with particular emphasis on the long-term effects on the fetus.


  • Pregnancy: Interactions between the embryo and corpus luteum

    by M.R. Johnson, V.N. Bolton, A.F. Riddle, V. Sharma, K. Nicolaides, J.G. Grudzinskas, W.P. Collins

    A total of 102 patients who had become pregnant following in-vitro fertilization (IVF) and embryo transfer were studied at weekly intervals between 4 and 14 weeks gestation. The pregnancies were classified as follows: (i) normal singleton, n = 52; (ii) normal twin, n = 24; (iii) heterotopic, n = 4 (weeks 4–8 only); and (iv) anembryonic with a viable intra-uterine singleton, n = 22. The serum concentrations of human chorionic gonadotrophin (hCG), Schwangerschaft protein-1 (SP-1) and pregnancy-associated plasma protein-A (PAPP-A), oestradiol and progesterone were measured. The mean serum concentrations of HCG, SP-1 and PAPP-A were significantly less in heterotopic than in singleton, singleton/anembryonic or twin pregnancies (P < 0.01–0.05), while those of progesterone and oestradiol were not different at any time. There were no significant differences between the serum concentrations of any of the substances analysed in singleton/anembryonic and singleton pregnancies, but the concentrations of all the substances analysed were significantly greater in twin pregnancies from as early as 7 weeks (P < 0.01–0.05). These data show that in heterotopic pregnancies trophoblast function is reduced, as suggested by the lower concentrations of the placental proteins. Despite this the concentrations of oestradiol and progesterone, derived predominantly from the corpus luteum between 4 and 8 weeks, are equivalent to those found in twin pregnancies, and greater than those found in singleton and singleton/ anembryonic pregnancies. These findings support the notion that although HCG may rescue the corpus luteum it does not subsequently have a direct effect on its function, and suggest that the embryo may influence corpus luteum function.


  • Pregnancy: Corpus luteum failure in ectopic pregnancy

    by M.R. Johnson, A.F. Riddle, R. Irvine, V. Sharma, W.P. Collins, K.H. Nicolaides, J.G. Grudzinskas

    The endocrinology of ectopic pregnancy was studied in order to investigate the origin of the discordance in the circulating amounts of human chorionic gonadotrophin (HCG) and those of oestradiol and progesterone. Serial maternal blood samples were obtained at 4–9 weeks gestation from 93 patients who became pregnant following in-vitro fertilization and embryo transfer including 10 ectopic, 21 anembryonic and 62 normal singleton pregnancies. The samples were analysed for HCG, Schwangerschaft protein-1 (SP-1), pregnancy-associated plasma protein-A (PAPP-A), progesterone and oestradiol. In ectopic pregnancies, concentrations of all substances analysed were significantly reduced compared to singleton pregnancies from 5 weeks gestation (P < 0.05−0.001) but they were not significantly different from those of anembryonic pregnancies. In ectopic pregnancies, associations were found between the concentration of both HCG and SP-1 and those of progesterone and oestradiol. No associations were found between PAPP-A and any other substances analysed. This may be due to insensitivity of the PAPP-A assay; alternatively PAPP-A concentrations may be differentially reduced in ectopic pregnancy. These findings suggest that progesterone and oestradiol are derived from the corpus luteum in early ectopic pregnancy but that the corpus luteum fails rapidly and the dominant source of both hormones becomes the trophoblast as early as 5 weeks.


    • 1 September 1993
      • Vol. 8  (9)

    Corpus luteum failure in ectopic pregnancy.

    by M R Johnson, A F Riddle, R Irvine, V Sharma, W P Collins, K H Nicolaides, J G Grudzinskas


    • 1 September 1993
      • Vol. 8  (9)

    Interactions between the embryo and corpus luteum.

    by M R Johnson, V N Bolton, A F Riddle, V Sharma, K Nicolaides, J G Grudzinskas, W P Collins


  • Placental and ovarian hormones in anembryonic pregnancy

    by M.R. Johnson, A.F. Riddle, V. Sharma, W.P. Collins, K.H. Nicolaides, J.G. Grudzinskas

    The circulating levels of human chorionic gonadotrophin (HCG), pregnancy-associated plasma protein-A (PAPP-A), Schwangerschaft protein 1 (SP-1), oestradiol and progesterone were measured in 81 pregnant patients between 4 and 11 weeks gestation, following in-vitro fertilization and embryo transfer. The patients were divided as follows: singleton anembryonic pregnancies, n = 22; singleton pregnancies which spontaneously aborted following the demonstration of fetal heart activity, n = 7; and normal singleton pregnancies, n = 52. The levels of all substances measured were significantly reduced in women with anembryonic compared to those with singleton pregnancies which proceeded to term. The serum levels of SP-1, weeks 6–8 (P < 0.01); HCG, weeks 6–8 (P < 0.05); oestradiol, weeks 5–8 (P < 0.05) and progesterone, weeks 6–8 (P < 0.05), were lower in anembryonic pregnancies than in those of pregnancies which spontaneously aborted. These differences may be a reflection of the fact that miscarriage, after the demonstration of fetal heart activity, represents fetal demise at a later stage in pregnancy. In anembryonic pregnancies, significant associations were found between HCG and both oestradiol and progesterone levels from weeks 6 and 8, suggesting that in the absence of an embryo, HCG is the prime determinant of steroid synthesis by the corpus luteum.